cefoperazone has been researched along with Critical Illness in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dang, ZL; Li, B; Qin, HY; Rao, Z; Wei, YH; Wu, XA; Zhu, L | 1 |
| Fang, Q; Fang, XL; Hu, J; Lai, YX; Xiao, YH; Zheng, Y | 1 |
| An, R; Du, Z; Gao, C; Sun, Z; Tong, J; Yu, K | 1 |
1 trial(s) available for cefoperazone and Critical Illness
| Article | Year |
|---|---|
Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
Topics: Acinetobacter baumannii; Adult; Aged; Anti-Bacterial Agents; Cefoperazone; Critical Illness; Female; Hemofiltration; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Sulbactam; Young Adult | 2016 |
2 other study(ies) available for cefoperazone and Critical Illness
| Article | Year |
|---|---|
Determination of Total and Unbound Meropenem, Imipenem/Cilastatin, and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients.
Topics: Cefoperazone; Chromatography, High Pressure Liquid; Cilastatin; Cilastatin, Imipenem Drug Combination; Critical Illness; Drug Monitoring; Humans; Imipenem; Meropenem; Plasma; Sulbactam; Tandem Mass Spectrometry | 2020 |
Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Topics: Adult; Afibrinogenemia; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Blood Coagulation Tests; Case-Control Studies; Cefoperazone; Critical Illness; Female; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Sulbactam; Tigecycline | 2020 |